Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 21,022 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions: Venetoclax, Umbralisib, Ublituximab, Lenalidomide; Drug · Biological
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, New York • Cleveland, Ohio

Conditions: Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Cytarabine, Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Biological · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: The Bronx, New York • Philadelphia, Pennsylvania

Conditions: Food Hypersensitivity
Interventions: cow's milk, peanut powder; Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 4 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Allergy
Interventions: Skin Testing; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Asthma
Interventions: Mometasone furoate 220, KoKo Spirometry, Mometasone furoate 440, Oscillometry; Drug · Device
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: VAK694, VAK694 placebo, QAX576, QAX576 placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Rhinitis, Allergic, Seasonal, Hay Fever
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 6
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
Interventions: Idecabtagene vicleucel, Lisocabtagene maraleucel; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 50 participants
Timeline: 2023 – 2038
U.S. locations: 4
States / cities: Portland, Oregon • Dallas, Texas • Salt Lake City, Utah + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: DHA Treatment, Placebo for DHA; Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Up to 5 Months
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 9
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 6 more

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Carboplatin, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Lenalidomide, Rituximab; Drug · Other · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 12
States / cities: Jacksonville, Florida • Urbana, Illinois • Iowa City, Iowa + 9 more

Conditions: Type 1 Diabetes
Interventions: Control-IQ Technology v1.5; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more

Conditions: Eosinophilic Esophagitis
Interventions: Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule; Diagnostic Test · Other · Drug
Lead sponsor: Claire Daniels; Federal
Eligibility: 6 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions: Mild dose cannabis, Low dose cannabis, Cannabis; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Islet transplantation; Drug
Lead sponsor: Rodolfo Alejandro; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Leukemia
Interventions: docetaxel; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 200
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 148 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Encinitas, California • Fountain Valley, California • Monterey, California + 3 more

Conditions: Asthma
Interventions: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis
Interventions: memory retraining exercises, placebo control memory exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 30 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: HIV-1, HIV Infections
Interventions: TMC114, Ritonavir; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: Waldenstrom Macroglobulinemia
Interventions: epcoritamab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Stem Cell Transplant Failure
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections, Pregnancy
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 69
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 40 more

Search by objective public record fields.

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Oral Immunotherapy for Peanut and Mammalian Meat Allergies

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

Onset and Duration of Mometasone by Oscillometry and Spirometry

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Nutritional Intervention to Prevent Diabetes

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

PS230005 Control-IQ 1.5 Post-Approval Study

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

Effects of Vaporized Marijuana on Neuropathic Pain

Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

Combination Study for High Risk Multiple Myeloma Patients

VENTURI (VENTilation Using Respiratory Imaging)

Improving New Learning and Memory in Multiple Sclerosis

A Study in Subjects With Moderate Atopic Dermatitis

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)

Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)

A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies